Multicellular spheroids of A549 and A549-iRFP as an in vitro model of lung cancer by Pei, Xinyu
University of the Pacific 
Scholarly Commons 
University of the Pacific Theses and 
Dissertations Graduate School 
2020 
Multicellular spheroids of A549 and A549-iRFP as an in vitro 
model of lung cancer 
Xinyu Pei 
University of the Pacific, x_pei@u.pacific.edu 
Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Pei, Xinyu. (2020). Multicellular spheroids of A549 and A549-iRFP as an in vitro model of lung cancer. 
University of the Pacific, Thesis. https://scholarlycommons.pacific.edu/uop_etds/3689 
This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been 
accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of 
Scholarly Commons. For more information, please contact mgibney@pacific.edu. 
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Scholarly Commons
1 
 
MULTICELLULAR SPHEROIDS OF A549 AND A549-IRFP CELLS AS AN IN VITRO 
















In Partial Fulfillment of the 
 
Requirements for the Degree of 
 
MASTER OF SCIENCE 
 
 
Thomas J. Long School of Pharmacy and Health Sciences 



















MULTICELLULAR SPHEROIDS OF A549 AND A549-IRFP CELLS AS AN IN VITRO 






















Thesis Advisor: Xin Guo, Ph.D. 
 
Committee Member: Miki Susanto Park, Ph.D. 
 
Committee Member: Myo-Kyoung Kim, Pharm.D., BCPS 
 







I would like to express my sincere gratitude to my advisor Dr. Xin Guo for his patience 
and guidance through my two years of Graduate School.  I am truly grateful to have the 
opportunity to work with him, and really enjoyed the environment of freedom he created in the 
lab.  I must say thanks to Dr. Guo for his insights, encouragement and continuous support when I 
was struggling with my experiments.  His advice on both research and my personal life have 
been invaluable. 
I would like to acknowledge my thesis committee members Dr. Miki Susanto Park and 
Dr. Myo-Kyoung Kim for their time, support, and invaluable suggestions on my thesis.  I would 
like to thank Dr. Xiaoling Li, for his insights on my research and introducing the program 
between University of the Pacific and China Pharmaceutical University.  I would like to thank 
Dr. William K. Chan and Dr. John Livesey for providing access to instruments crucial for my 
research.  I would like to thank Dr. Melanie Felmlee for her advices on my research. I would also 
like to thank all PCSP faculty and staff. 
I would like to thank Guo’s group members both past and present.  Thanks to Dr. Yifan 
Lu, Dr. Mallika Vadlamudi, Dr. Shen Zhao, Yingbo Huang, Ruiqi Huang, Zhongyue Yuan, 
Zizhao Xu and Yong Zhu for their insights and supports on my research.  It is my great pleasure 
of working with them over the years. 
I thank all my friends, Hao Wei, Fang Liu, Dengpan Liang, Dr. Jinyun Chen, Dr. Chao 
Feng, Dan Shao, You Li, Zhixin Lu, Xuequn Huang, Yiyuan Wang, Qing Zhang, Yujie Yang, 
Jingda Wang, Yuntao Zhang, Rui Xiong, Michael Ng, Jensen Spear, Ryan Murray, Mason 
Webber, Hamed Salmanzadeh Dozdabi, Arjun Patel, Md Tariqul Tuhin, Toufiq UI Amin, Dr. 
4 
 
Arindom Pal, Nahid Sultana, and Md Rahatullah Razan for happiness and support they brought 
me. 
Finally, I would like to express my gratitude to my parents and grandparents for 
providing me with unfailing support and continuous encouragement throughout my years of 





MULTICELLULAR SPHEROIDS OF A549 AND A549-IRFP CELLS AS AN IN VITRO 






By Xinyu Pei 
 




Lung cancer is the second most common cancer in both men and women around the 
world, and 85% of it is non-small cell lung cancer (NSCLC).  It is estimated that in 2020, there 
will be 228,820 cases of lung cancer and 135,720 deaths from lung (American Cancer Society, 
2020).  The prognosis of lung cancer is poor (<10% 5-year survival rate for advanced NSCLC), 
which can be partly attributed to limitations in bio-models that screen for drug candidates against 
lung cancer. 
Traditionally, the most commonly used in vitro method for screening therapeutic drugs is 
monolayer cell cultures, which are reproducible, convenient and of low cost.  However, 
monolayer cell culture models are unable to reproduce many properties of in vivo solid tumors 
such as the morphological features and the microenvironment including cellular heterogeneity, 
cell-cell interactions, and gradients of oxygen, pH, and nutrients.  Consequently, excessive 
ineffective drug candidates would proceed to animal studies, which would prolong the time for 
drug development and increase the overall cost of drug discovery. 
In consideration of the foregoing, in vitro models of cancer based on three-dimensional 
multicellular spheroids (MCS) have been developed in our group to characterize drug candidates 
and drug delivery systems.  Compared to monolayer cells, the multicellular spheroids can better 
simulate drug penetration and drug resistance in solid tumors.  Therefore, the multicellular 
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spheroids represent a more clinically relevant in vitro model to evaluate the efficacy of 
anticancer drugs. 
This project aims to characterize MCS of lung cancer cells as an improved platform to 
evaluate drug candidates against lung cancer.  Cell viability assays on cisplatin, carboplatin, 
gemcitabine, and doxorubicin have been conducted to compare the anticancer activities between 
conventional monolayer cells and the corresponding MCS of human lung cancer cell lines, A549 
and A549-iRFP (fluorescently labeled A549 cells).  Higher concentrations of the tested 
anticancer drugs is consistently needed to inhibit 50% the cell viability in MCS than the 
corresponding monolayer cells of A549 and A549-iRFP. 
Cycled dosing schedules based on guidelines for NSCLC from National Comprehensive 
Cancer Network have been designed and used to treat A549-iRFP MCS.  The A549-iRFP MCS 
have been exposed to anticancer drugs either continuously, or in pulsed concentrations according 
to the drugs’ pharmacokinetics (PK).  The continuous drug exposure has been found to inhibit 
more cell growth in MCS than the corresponding PK-mimetic drug exposure.  Such phenomenon 
would bring significant positive bias to the activity of many anticancer drug candidates during 
their early discovery and development. 
Taken together, MCS of A549 and A549 iRFP cells better represent the efficacy of 
anticancer drugs in clinic than the monolayer.  MCS can also be used to evaluate anticancer drug 
candidates by pulsed drug exposure based on their pharmacokinetics, and by commonly used 
cycled dosing regiments to better predict their efficacy in clinical settings. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Cancer and Anticancer Drug Development Process 
Drug development is a long process where a potential new drug must be identified and 
evaluated in preclinical studies which involves in vitro cell culture and in vivo animal studies.  
Then the drug candidates must go through four phases of clinical trials before being approved by 
the FDA.  In theory, the preclinical studies at the early stages of drug discovery process should 
improve the success rate of the clinical trials but in reality, the approval rate of anticancer drug is 
exceptionally low despite of the promising preclinical results.  A recent report given by 
Biotechnology Innovation Organization (BIO) entitled “Clinical Development Success Rates 
2006-2015” pointed out that oncology drug candidates had only 5.1% rate of success from phase 
I compared to  the success rate of 11.9% for drug candidates of all other indications (Thomas et 
al., 2016).  This low success rate of oncology drug candidates could be partially explained by the 
preclinical cancer models that pharmaceutical companies use for the first-pass screening of the 
drug candidates.  The main strategy to select drug candidates in vitro is to evaluate their 
activities in cultures of two-dimensional (2D) monolayer cells.  It is only in recent years that 
more sophisticated, three-dimensional (3D) cell cultures were introduced as an improved model 
to screen anticancer drugs in vitro. 
1.2. Traditional in vitro Drug Screening in Monolayer Cell Culture 
Monolayer cell culture is the most commonly used drug screening method in vitro.  
Advantages of monolayer cell cultures include fast assessment, simplicity, convenience, good 
reproducibility and low cost.  However, this method does not reproduce many properties of solid 
tumor in vivo.  The monolayer cells have poor cell-cell interactions, poor cell-extracellular 
interactions, negligible cancer cell heterogeneity, incorrect morphology and substantially 
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different microenvironment.  Consequently, a lot of unviable drug candidates have been 
forwarded from such cell culture studies to further studies in vivo, which caused extensive waste 
of time, money and experimental animals. 
1.3. Improved in vitro Drug Screening in Three-Dimensional Cell Culture  
Because of the above-mentioned limitations of the monolayer cells, it is necessary to 
reproduce 3D architecture of solid tumor to better understand the biology of cancer, and to better 
identify anticancer drug candidates.  3D cell cultures can meet these needs and can be developed 
into better platforms of in vitro drug screening.  In 3D cell cultures, cells can be aggregated to 
form clusters in a spheroid shape, which is called multicellular spheroid (MCS).  In this way, 
multicellular spheroids of cancer cells can be fabricated to mimic many more features of solid 
tumors than monolayer cells in culture. 
1.3.1. Morphological Features   
Multicellular spheroids are cell aggregates with a three-dimensional structure that is more 
similar to solid tumor in morphology than monolayer cells.  Well-formed spheroids normally 
show a spheroid shape under scanning electron microscope or a round shape under phase 
contrast microscope.  The MCS morphology of different cell lines vary; some form tight 
spheroids while others form loose MCS (as shown in Figure 1). 
 
 
Figure 1. Morphology of tight and loose MCS after 24h cultivation. (A, B). Highly compact 
MCS formed by MCF7 and T-47D cells; (C, D) Loose MCS formed by MDA-MB-231 and 




1.3.2. Hypoxia Microenvironment   
Hypoxia is one of the hallmarks in solid tumors, where the oxygen level gradually 
reduced from outer regions to inner areas.  This occurs as a consequence of multiple factors, 
including rapid oxygen consumption, increased diffusion distance from vasculature to cells, 
irregular vascular geometry, and low oxygen capacity in blood (Hammond et al., 2014; Höckel 
& Vaupel, 2001).  Such an oxygen gradient can also be seen in MCS, as confirmed in many 
studies using microelectrodes, ethidium-calcein staining, and/or measurements of hypoxia 
inducible factor (HIF) and its downstream target gene, VEGF.  (Bredel-Geissler, Karbach, 
Walenta, Vollrath, & Mueller-Klieser, 1992; Riffle & Hegde, 2017; Zanoni et al., 2016).  For 
example, a 3.3-fold increase of HIF-1α level in MCS was detected compared with monolayer of 
HeLa cells (Rodríguez-Enríquez et al., 2008).  One possible reason for the oxygen gradient in 
MCS would be that cells at the peripheral regions consumes most oxygen as it diffuses to inner 
cells (Mueller-Klieser & Sutherland, 1982). 
1.3.3. Altered Cell Metabolism   
Cells normally obtain energy through oxidative phosphorylation under aerobic 
environment, whereas in solid tumor, even in the presence of oxygen, energy is preferably 
obtained from glycolysis, when lactate is generated as by-product (Vander Heiden, Cantley, & 
Thompson, 2009; Warburg, 1956).  This alteration of metabolism in solid tumors is known as the 
Warburg.  MCS also shows the Warburg effect by the increased mRNA expression of glucose 
transporter 1 (GLUT-1) and lactate dehydrogenase (LDHA).  For example, GLUT-1 expressed 
on PANC-1 MCS was around 6.5 times higher than the corresponding monolayer cells and the 
LDHA expression was 2.8 times higher (Longati et al., 2013).  Another example, GLUT-1 
17 
 
expression increased 2.6-3.4 times in HeLa MCS compared to the corresponding monolayer cells 
(Rodríguez-Enríquez et al., 2008). 
1.3.4. Acidic Microenvironment   
In solid tumor, cancer cells generate excess amount of lactate (pKa=3.9) and hydrogen 
ions (H+) as a result of glycolysis, which leads to a fall in intracellular pH (pHi).  In order to 
counter the acidic pHi, protons are exported across the plasma membrane by various transporters 
such as H+-ATPase, Na+-H+ exchange, carbonic anhydrases and monocarboxylate transporter 
(MCT), which maintains a favorable pHi of 7.0-7.2 but generates an acidic extracellular 
microenvironment (Parks, Chiche, & Pouysségur, 2013; Swietach, Vaughan-Jones, & Harris, 
2007).  This acidic microenvironment in tumors has been verified in many studies.  In one MCF-
7 breast cancer tumor, extracellular pH in the peripheral region of the tumor about 10 μm away 
from capillary blood vessel wall is around 7.3, but drops to 6.7 in a region about 400 μm away 
from the blood vessel wall (G. Helmlinger, Yuan, Dellian, & Jain, 1997).  Acidification also 
takes place inside MCS as a pH difference of 0.3–0.4 units is seen between the center (pH 6.9–
7.05) and the periphery (pH 7.3–7.4) in MCS of many cancer cell lines including HT29, V79-
379A, EMT6, U-138 MG, U-251 MG U-118 MG and HTh7 (Carlsson & Acker, 1988). 
1.3.5. Cell-Cycle Arrest   
Rapidly growing cancer cells experience hypoxia, nutrient deficiency and acidic 
microenvironment, which induces necrotic cell death especially in the inner region of solid 
tumors or spheroids.  Many studies have demonstrated that MCS possesses a necrotic zone in the 
center, a proliferating zone at the periphery and some quiescent cells in between, which cannot 
be seen in monolayer cell cultures.  MCS of various types of cancers, such as human breast 
cancer, colon cancer and ovarian cancer is found to overexpress p27, a quiescence marker, by 
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1.2~15 fold compared to the corresponding monolayer cells (Croix et al., 1996).  In addition, 
DLD-1 human colon adenocarcinoma MCS is found to express the proliferation marker Ki-67 
mostly  at the periphery, and yet the quiescence marker p27 at the center (Mellor, Ferguson, & 
Callaghan, 2005). 
1.3.6. Cellular Components   
Besides carcinoma cells, solid tumors are heterogenic, and consist of many other types of 
cells including immune cells (e.g., T lymphocytes, B lymphocytes, macrophages, NK cells and 
lymphatic endothelial cell), tumor vascular endothelial cells, cancer-associated fibroblasts, 
pericytes and adipocytes (Balkwill, Capasso, & Hagemann, 2012).  Even though these cells are 
non-malignant, they play important roles in tumor angiogenesis, progression, invasion, 
metastasis and resistance by interacting with the surrounding cancer cells and with one another 
(M. Wang et al., 2017).  Cellular heterogeneity can also be achieved in MCS by co-culturing 
stromal cells with cancer cells.  For example, the coculture of colorectal tumor spheroids with 
immune cells presented a relevant tool to study antitumor potential of immunomodulatory 
antibodies (Courau et al., 2019); a triple co-culture of pancreatic cancer cells with fibroblasts and 
endothelial cells closely mimicked the resistance to anticancer treatments (Lazzari et al., 2018). 
1.3.7. Extracellular Matrix (ECM) Deposition  
Extracellular matrix is a non-cellular matrix of biopolymers in all tissues.  ECM is 
composed of fibrous proteins (e.g., collagens, elastins, fibronectins, and laminins) and 
proteoglycans (e.g., glycosaminoglycan).  In normal tissues, ECM provides both structural and 
biochemical support in regulating cell proliferation, cell adhesion and cell signaling (Frantz, 
Stewart, & Weaver, 2010).  In tumors, ECM protein dynamics become abnormal and the 
deposition is elevated, such as increased collagen found in breast cancer (Levental et al., 2009; 
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Provenzano et al., 2006).  The ECM proteins are also found overexpressed in U-118 MG glioma 
and HTh-7 thyroid spheroids (Nederman, Norling, Glimelius, Carlsson, & Brunk, 1984).  ECM 
proteins (e.g., proteoglycan and fibronectin) are expressed more in three dimensional spheroids 
than in the corresponding monolayers (Glimelius, Norling, Nederman, & Carlsson, 1988). 
1.3.8. Cell-ECM and Cell-Cell Physical Interactions   
In a solid tumor, cell-ECM interactions (indicated by β1-integrin level) and cell-cell 
interactions (indicated by E-cadherins level) are elevated compared to normal tissues.  Such 
elevation is associated with cancer cell signaling, proliferation, migration and invasion (Casey et 
al., 2001; Walker, Mojares, & Del Río Hernández, 2018; Xiong & Xu, 2016).  Cell-ECM and 
cell-cell physical interactions are found to be more pronounced in MCS than the corresponding 
monolayer cell cultures due to MCS’ spatial architecture.  β1-integrins was significantly 
increased in 3D epithelial ovarian cancer cell lines (OV-MZ-6 and SKOV-3) compared to 2D 
(Loessner et al., 2010).  E-cadherin was significantly higher in Huh7 spheroid compared to 2D 
(Jung et al., 2017). 
1.3.9. Physical Barrier   
Elevated ECM protein deposition, cell-ECM interactions and cell-cell physical 
interactions in solid tumors are also important concerns for anticancer drug development because 
they increase tissue density and yield a physical barrier that limits the penetration of anticancer 
drugs (Minchinton & Tannock, 2006). 
1.4. Lung Cancer 
1.4.1. Lung Cancer and its Epidemiology   
According to American Cancer Society, lung cancer is the second most common cancer 
in both men and women (excluding skin cancer) and the leading cause of cancer death, making 
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up nearly 25% of all cancers.  It is estimated that in 2020, there will be about 228,820 new cases 
of lung cancer and about 135,720 deaths from lung cancer (American Cancer Society, 2020). 
1.4.2. Types of Lung Cancer   
There are two types of lung cancers, small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC), which need different treatment.  About 15% of lung cancers are small cell 
lung cancer (SCLC) and about 85% are non-small cell lung cancer (NSCLC).  NSCLC has three 
main subtypes: adenocarcinoma, squamous cell carcinoma and large cell carcinoma. 
1.4.3. Staging   
The progression of non-small cell lung cancer consists of 4 stages: 
Stage I: Cancer is localized only in one lung and has not spread to any lymph nodes. 
Stage II: Cancer is localized in lung and nearby lymph nodes. 
Stage IIIA: Cancer has spread to lymph nodes but only on the same side of the chest where 
cancer started growing. 
Stage IIIB: Cancer has spread to lymph nodes on the opposite side of the chest, or above the 
collar bone. 
Stage IV: Cancer has spread to both lungs, or to fluid in the proximity, or to distant organs. 
1.4.4. Treatment   
Surgery, radiation, chemotherapy (chemo), targeted treatment and immunotherapy are 
used to treat NSCLC, either alone or in combination.  Surgery is mostly applied to stage I and 
stage II patients to remove tumor.  Radiation therapy is used alone or in combination with 
chemo. 
Chemotherapy can be given after surgery to kill remaining cancer cells, a strategy known 
as adjuvant chemotherapy.  Moreover, chemotherapy can be given before surgery to shrink the 
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tumor size, a strategy known as neoadjuvant chemotherapy.  In addition, chemotherapy is also 
used to treat unresectable cancers.  The commonly used chemo drugs include cisplatin, 
carboplatin, vinorelbine, docetaxel, gemcitabine, etoposide and pemetrexed.  Combination of 
two chemo drugs are usually used, which often includes cisplatin or carboplatin plus one other 
drug.  Patients with certain gene mutations can be treated with targeted therapy drugs.  For 
example, Osimertinib, Afatinib, Erlotinib or Gefitinib is used for patients who are positive of 
EGFR mutations, Alectinib or Brigatinib for ALK mutations, Crizotinib or Entrectinib for ROS1 
mutations, and Dabrafenib plus Trametinib for BRAF mutations.  Patients who have high level 
of PD-L1 protein expression can be treated with immunotherapy, such as pembrolizumab. 
1.5. Hypothesis and Specific Aims 
1.5.1. Statement of Purpose   
Because of the afore-mentioned advantages of MCS to mimic many more features of 
solid tumors than monolayer cell cultures, the purpose of this project is to characterize MCS of 
lung cancer cells as an improved platform to evaluate drug candidates against lung cancer.  Two 
human lung cancer cell lines will be used, A549, which is one of the most investigated cell lines 
of NSCLC, and A549-iRFP-Puro (A549-iRFP), which is derived from A549 and stably 
expresses near-infrared fluorescent protein for convenient detection. 
1.5.2. Hypothesis   
This project aims to test the hypothesis that the sensitivity of MCS A549 and A549-iRFP 
to anticancer drugs better reflect the drugs’ efficacy against lung cancer in clinic than the 
corresponding monolayer cells. 
1.5.3. Specific Aims   
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This project has the following three specific aims.  Aim 1, to construct A549 MCS and 
A549-iRFP MCS; Aim 2, to compare the sensitivity of A549 and A549-iRFP MCS to several 
well-established chemotherapy drugs with the sensitivity of the corresponding A549 and A549-
iRFP monolayers; Aim 3, to evaluate the viability of the fluorescent A549-iRFP MCS after 







CHAPTER 2: CONSTRUCTION OF MCS OF A549 AND A549-iRFP 
 
2.1. Introduction 
2.1.1. A549 and A549-iRFP Cells   
A549 is adenocarcinoma human epithelial cells, developed from the lung of a 58-year old 
male Caucasian.  It has been used as a model of NSCLC in many studies, from basic mechanism 
of lung cancer to novel drug development (Liebmann et al., 1993).  A549-iRFP-Puro is a 
polyclonal population of the human lung carcinoma cell line A549 (ATCC® CCL-185™) that 
stably express near-infrared fluorescent protein (iRFP) and can be selected using puromycin.  
The fluorescence ex/em is 690/713 nm which makes in vivo and ex vivo imaging of implanted 
cells easier, since biological tissues have lower absorption and less autofluorescence at 600 to 
1000 nm (Hilderbrand & Weissleder, 2010). 
2.1.2. Methods for MCS Formation   
In recent years, various methods have been developed for the formation of MCS.  It is 
important to fabricate multicellular spheroids with controllable and uniform size, biological 
functions and 3D microenvironment that best mimics tumors in vivo.  Conventional and 
commonly used methods can be divided into scaffold-based and scaffold-free methods. 
In a scaffold-based method, as its name suggests, scaffold is applied to help form MCS 
that provides not only the 3D structure but also cell-cell and cell-matrix interactions.  Hydrogels 
are widely used as scaffold, which includes natural hydrogel (e.g., collagen, Matrigel™ and 
hyaluronic acid-based hydrogels) and synthetic hydrogel (e.g.,  Poly(ethylene glycol) (PEG), 
Poly(N-isopropylacrylamide) (PNIPAM) and Poly(Ꜫ-carpolacton) (PCL)) (Cui, Hartanto, & 
Zhang, 2017).  There are two types of scaffold-based methods: matrix-based method and 
microfabrication method.  A typical type of scaffold-based methods is matrix-based method, in 
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which MCS could be either formed on top of the matrix or inside the matrix.  A more complex 
scaffold-based method is the microfabrication method, it involves hydrogel and needs to use 
specially made equipment such as micropatterned plates or microfluidic platforms. 
In a scaffold-free method, spinner flasks, NASA rotating flasks and pellet culture method 
involves agitation, while other methods such as hanging drop, ultra-low cell attachment plate 
method, liquid overlay and magnetic levitation and 3D bioprinting are agitation-free.  
Descriptions and comparisons of the above-mentioned methods are listed in Table 1.  Even 
though each method has significant limitations, they could be combined to complement one 







Table 1  
Comparison of Common 3D MCS Formation Methods  

























Cells are either seeded on top 
of a solidified layer of matrix 
















Lee, Kenny, Lee, 
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Cells aggregate and grow in a 
hydrogel-coated or filled 
microchannels in a perfusion 
system 









suitable for HTS 
(Lim & Park, 


























Cells aggregate by preventing 
their adhesion on material 
surface via constant stirring Simple to perform; 





due to shear 
stress; Not for 
large scale 






Cells aggregate by preventing 
their adhesion on material 
surface via constant rotating in 
a microgravity environment 




Cells aggregate by 
centrifugation 
Simple to perform; 
Rapid formation 
Cells may be 
damaged by 
shear stress 












Cells aggregate spontaneously 
in the bottom of a droplet of 
culture medium relying on 
gravity 
Low cost; Uniform 
size and shape; 
Simple to perform; 
Rapid formation 













Cells aggregate by culturing 
them on a hydrophilic, 
neutrally charged coating 
Easy to image; 
Easy to change 
media; Easy to 
harvest; Long term 
culture; Suitable 
for HTS 




Cells aggregate by culturing 
them on a concave non-
adherent substrate 















Magnetically labeled cells 
(incubated with magnetic 
nanoparticles) are pulled up 
under magnetic forces where 
magnet is placed on top of the 
plate 
Rapid formation 
Not for large 
scale; Cells need 
to be pretreated 
with magnetic 
nanoparticles 





(Table 1 Continued) 





Magnetically labeled cells 
(incubated with magnetic 
nanoparticles) are pulled down 
under magnetic forces where 
magnet is placed beneath the 
plate 
  (Tseng et al., 
2015) 






2.1.3. Characterization and Evaluation of MCS   
Many assays have been used to evaluate MCS growth and its response to growth factors 
and drug treatments (listed in Table 2).  Methods usually used on monolayer can also be used on 
MCS.  However, although MTT assay has been used on MCS, it is not highly recommended 
since it is harder to penetrate MCS.  Instead, CellTiter-Glo® can be a substitute assay to quantify 






Comparison of Assay Methods Used in MCS 
 










fragmentation TUNEL assay 
(Gunther, Pawlak, Damasceno, Arnold, & Terzis, 2003; 
Gabriel Helmlinger, Netti, Lichtenbeld, Melder, & Jain, 
1997) 
Caspase activity Caspase assays (Kessel et al., 2017) 
Phosphatidylseri






G6PD (W. Wang et al., 2018) 
LDH assay (Xu, Ma, & Purcell, 2003) 
Damage of cell 
membrane 7-AAD (Patra, Peng, Liao, Lee, & Tung, 2016) 
Cell 
proliferatio
n and cell 
cycle assay 
Vital dyes 
Calcein-AM (Patra et al., 2016) 
Trypan blue (Ivanov et al., 2014) 
Propidium 
iodide (Andrea & Manfred, 2006) 






Glo® (Kessel et al., 2017; Vinci et al., 2012) 
ViaLight™ 
plus kit (Nie, Garner, & D'Souza, 2017) 
Tetrazolium MTT assay (Ho, Yeap, Ho, Rahim, & Alitheen, 2012) MTS assay (Yeon et al., 2013) 
Resazurin Alamar blue assay (Ivanov et al., 2014) 







microscope (Vinci et al., 2012) 
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2.2.1. Materials  
A549 cell line was purchased from ATCC (VA, US).  A549-iRFP cell line was purchased 
from Imanis Life Sciences (MN, US).   RPMI 1640, DMEM, Collagen, Trypsin-EDTA, 1% 
penicillin-streptomycin and Live/DEADTM Cell Imaging Kit were purchased from Thermo-
Fisher.  Puromycin was purchased from Alfa Aesar (MA, US).  Fetal bovine serum was 
purchased from Gemini Bio-Products (CA, US).  Ultra Cruz® Black/Clear Flat bottom 96-well 
microplates were purchased from Santa Cruz (CA, US).  White Flat Bottom 96-well microplates 
and 96-well Spheroid microplates were purchased from Corning Life Science (NY, US).  
CellTiter 96® AQueous One Solution Cell Proliferation Assay and CellTiter-Glo® 3D Cell 
Viability Assay kits were purchased from Promega Corporation (Madison, WI, US).  Cisplatin, 
Doxorubicin Hydrochloride was purchased from BIOTANG Inc. (MA, US).  Carboplatin was 
purchased from ChemScene llc (NJ, US).  Paclitaxel and Gemcitabine Hydrochloride were 
purchased from LC Laboratory (MA, US) 
2.2.2. Cell Culture Maintenance   
A549 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum 
(Gemini, CA, US) and 1% Penicillin-Streptomycin (Corning Life Science, NY, US).  A549-iRFP 
cells were maintained in DMEM supplemented with 10% fetal bovine serum (Gemini, CA, US), 
1% Penicillin-Streptomycin (Corning Life Science, NY, US), and 1 μg/ml puromycin (Alfa 
Aesar, MA, US).  Cells were grown in 5% CO2 at 37 °C and passaged at 85% confluence (3~4 
days). 
2.2.3. Formation of 3D MCS   
NSCLC cell lines A549 and A549-iRFP were seeded at 5000 cells in 100 µl growth 
media for each well with 0.3% collagen onto Corning 96-well spheroid microplates (Corning 
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Life Science, US), which were then centrifuged at 300 × g for 7 min by Eppendorf Centrifuge 
5810R.  Plates were incubated for 48 hours then supplemented with another 100 µl growth 
media.  Media was changed every other day by replacing 100 µl media in microplates with 100 
µl fresh media to ensure a total volume of 200 µl.  The growth and morphology of MCS were 
observed by Keyence (US) BZ-X700 fluorescence microscope. 
2.2.4. Characterization and Optimization of 3D MCS Viability Assay   
A549-iRFP cells were seeded at 3000 cells/well in 96-well spheroid microplates to form 
A549-iRFP MCS as described above.  Certain amount MCS were collected each time for 
experiment when diameter reaching around 350 µm, 550 µm, 750 µm, and 950 µm.  MCS were 
divided into 6 groups, according to the volume ratio between MCS with media and CellTiter-
Glo® 3D Cell Viability Assay varying from 1:1 to 1:6.  The total working volume was 200μl for 
each well.  Each group had 2 subgroups of a 5-minute shaking time as described in 3D cell 
viability assay’s protocol and another group of 10 minutes shaking time (see Table 1).  Assay 
was used as protocol except 5 more additional ratios of sample volume to reagent volume were 
added from 1:2 up to 1:6, and another set of groups was vigorously shaking for additional 5 
minutes other than the protocol.  In general, MCS were collected and transferred to opaque-
welled plates, assay was added to each well as calculated (see Table 1).  Microplates were 
vigorously mixed as its designated time group and incubated at room temperature for additional 
25 minutes.  The luminescence was then recorded by a Synergy HTX microplate reader (BioTek, 










5 min 10 min 
Vsample(μl) Vassay(μl) Vsample(μl) Vassay(μl) 
1:1 100.0 100.0 100.0 100.0 
1:2 66.7 133.3 66.7 133.3 
1:3 50.0 150.0 50.0 150.0 
1:4 40.0 160.0 40.0 160.0 
1:5 33.3 166.7 33.3 166.7 
1:6 28.6 171.4 28.6 171.4 
 
2.2.5. Imaging of Live/Dead in A549 3D MCS   
A549 cells were seeded at 5000 cells/well in 96-well spheroid microplates to form A549 
3D MCS as described above.  A549 MCS were transferred to a glass Petri dish when the 
diameter reached 500 µm and incubated with Live/DEADTM Cell Imaging Kit at room 
temperature for 45 minutes before washed 3 times with PBS buffer.  A549 3D MCS were 
imaged by a Leica DMIRE2 confocal microscope.  Excitations at 491nm and 561nm were used 
for live and dead dyes, respectively,; since the live dye can produce an intensive green 
fluorescence in live cells at ex/em ~494 nm/~517 nm, and dead dye gives a bright red 
fluorescence at ex/em ~528 nm/~617 nm.  Images were acquired with MetaMorph and analyzed 
by using ImageJ software. 
2.2.6. Data Analysis.   
Data are presented as mean ± standard deviation (SD) for assay characterization study.  
The statistical analysis is performed by two-way analysis of variance (ANOVA) for assay 
characterization study using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla, CA).  
Tukey’s multiple comparisons test analysis was performed to compare between groups.  Results 




2.3. Results and Discussion 
2.3.1. Formation of 3D A549 and A549-iRFP MCS   
Among methods described above, matrix, centrifugation and ultra-low attachment plate 
methods are used together in our lab to form spheroids.  Controllable and uniform size MCS 
were formed in both A549 and A549-iRFP with the use of 0.3% collagen and centrifugation at 
300 × g.  As is shown in Figure 2, MCS were tight and relatively round shape, and the size of 
MCS grew bigger over time in both cell lines.  Growth curves were also validated in volume and 
cellular viability, both of which increased over days (Figure 3). 
 
 
Figure 2. Morphology of MCS on day 1, 3, 5, 7, 9 and 11. Tight and relatively round shape 3D 
MCS were formed. Size of MCS grew bigger over days (represented by diameter). (A) 3D A549 






Figure 3. Growth curves of A549 and A549-iRFP MCS. Size of MCS (represented by volume) 
grew bigger over days so as viable cells (represented by cellular ATP, measured by 3D MCS 
viability assay). (A, B) 3D A549 MCS; (C, D) A549-iRFP MCS; same group of MCS as is used 
in Figure 2. 
 
2.3.2. Characterization and Optimization of 3D Cell Viability Assay Condition   
According to the 3D cell viability assay’s protocol, a volume of reagent equal to cell 
culture media present in each well should be added, and then vigorously mix for 5 minutes to 
induce cell lysis.  Plate is incubated for 25 minutes to stabilize the luminescent signal before 
reading.  However, considering MCS will probably grow very big at the end of our studies, 1:1 
ratio of MCS to reagent volume and 5 minutes mixing time may not be enough mixing.  
Insufficient mixing will result in inaccurate readouts, because less ATP will be released and 
result in underestimated luminescent signal level.  Therefore, in order to produce effective ATP 
extraction from MCS so that optimum assay performance can be achieved, higher ratios of 
reagent volume were added and longer mixing time was also being tested.  Among all the size 
ranges, there are no significant differences between 1:1 and each tested ratio (1:2, 1:3, …, 1:6), 
and no difference is seen between 5 minutes and 10 minutes mixing time (results shown in 
Figure 4), which means the amount of reagent used and time for mixing in protocol are enough 
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to lyse cells and can react thoroughly.  Therefore, 3D viability assay can be carried out as 
specified in the protocol’s steps, no adjustment needed to be done. 
 
 
Figure 4. 3D cell viability assay validated on different sizes of 3D A549-iRFP spheroids. There 
is no significant difference among different volume ratio between sample and assay in all sizes 
and shaking time being tested, and no significant difference under 5 minutes and 10 minutes 
shaking time in all sizes and ratio. (P>0.05 for two-way ANOVA). (A) 3D A549-iRFP spheroids 
at diameter ~350μm; (B) 3D A549-iRFP spheroids at diameter ~550μm; (C) 3D A549-iRFP 
spheroids at diameter ~750μm; (D) 3D A549-iRFP spheroids at diameter ~950μm. 
 
2.3.3. Distribution of Live and Dead Cells in 3D A549 MCS   
Figure 5A shows a cross section of a 3D MCS A549 that is 500 µm in diameter by 
confocal microscope, taken 200 µm from the bottom which is close to the core.  The green 
fluorescence is from fluorescent calcein representing live cells, red fluorescent comes from 
EthD-1 which represents dead cells.  From both confocal image (Figure 5A) and relative 
fluorescent intensity (Figure 5B), green signals can be seen more in peripheral area while red 
signals are more centered in the core.  This means live cells are located at outside layer while 
35 
 
dead cells are more accumulated in core area, which confirms that necrotic core is formed in 3D 
A549-iRFP at the size of 500 µm. 
This phenomenon can also be seen in 3D MCS A549-iRFP done by our lab previously, 
shown in Figure 6 (Yingbo, 2019).  The diameter of chosen MCS was also around 500 µm, and 
the cross section was also taken 200 µm from the bottom, using same experimental conditions.  
The distribution of green and red fluorescence signal in MCS shown in Figure 6 confirms the 
existence of necrotic core in 3D MCS of A549-iRFP. 
 
 
Figure 5. Confocal image of live/dead cells in A549 3D MCS. (A) Confocal image shows the 
distribution of live and dead cells in A549 3D MCS; (B) Relative fluorescent intensity profile 
indicates the distribution of live cells and dead cells vary in 3D A549 MCS; green fluorescent 





Figure 6. Confocal image of live/dead cells in A549-iRFP 3D MCS. (A) red fluorescent signal 
(B) green fluorescent signal (C) merged image of two signals (D) image of 3D A549-iRFP MCS 
taken in brightfield. 
 
2.4. Summary 
Round, tight and uniform MCS of both A549 and A549-iRFP are successfully 
constructed at selected seeding density on ultra-low attachment plates using collagen and 
centrifugation.  Their sizes are controllable and grows bigger over days.  Necrotic cores are 
located at the center of MCS on both cell lines when sizes reach 500 µm.  CellTiter-Glo®, a 3D 
cell viability assay, can be used to evaluate MCS viability after drug treatment under specified 
protocol procedures even when diameter is larger than 1000 µm. 
Of interest is that these MCS only consist of carcinoma cells, which does not have other 
type of cells that a solid tumor has, for example fibroblasts and endothelial cells.  Those 
components are important in mimicking solid tumor heterogenic cellular constitution which 
further support cell-cell and cell-matrix interactions.  However, because of the collagen we used, 
it provided the matrix for cells to grow and aggregate, leading to cells diversifying into 
proliferating cells, quiescent cells and non-proliferating cells.  Even though there is only one type 
of cell, we still developed MCS that mimics solid tumor better than monolayer cells. 
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In this way, our lab combined three methods to form A549 and A549-iRFP MCS 
successfully which are ready to be used in drug screening.  This method is quite novel and has 







CHAPTER 3: RESPONSE OF MCS TO ANTICANCER DRUGS COMPARED TO 
MONOLAYERS 
 
3.1. Introduction   
After the successful construction of A549 and A549-iRFP MCS, four anticancer drugs, 
namely cisplatin, carboplatin, gemcitabine and doxorubicin were chosen to be assessed on their 
ability to inhibit the growth of MCS.  These four anticancer drugs were chosen because they are 
widely used in A549 related studies, cisplatin and carboplatin are drugs of choice in clinical 
settings (Edelman, Quam, & Mullins, 2001; Punia, Raina, Agarwal, & Singh, 2017; Shali et al., 
2018; Teng et al., 2018; Varbanov, Kuttler, Banfi, Turcatti, & Dyson, 2019). Gemcitabine is 
more frequently used in squamous cell NSCLC while doxorubicin is indicated in small-cell lung 
cancer.  These two drugs are used as negative controls.  Four types of cell culture were used: 
A549 monolayer cells, A549 MCS, A549-iRFP monolayer cells, and A549-iRFP MCS due to the 
afore-mentioned advantages of MCS to mimic more features of solid tumors than monolayer cell 
cultures (Chapter I). 
3.1.1. Cisplatin   
Cisplatin is the first platinum-based anticancer agent.  It was approved by FDA in 1978.  
It exhibits broad spectrum of antitumor activity in various cancer types including testicular, 
ovarian, lung, head and neck, and bladder cancers.  It has several side effects, for example, 
serious emesis, neurotoxicity, and nephrotoxicity (which is often dose-limiting toxicity).  The 
mechanism of action is due to its interaction with DNA.  The chloride ligands of cisplatin are 
replaced by H2O molecules once inside cells, then covalently bind to the N7 site of purine base 
of DNA to form intrastrand crosslinks.  This cisplatin-DNA adducts distort the DNA duplex 
structure which block DNA replication and transcription (D. Wang & Lippard, 2005). 
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3.1.2. Carboplatin   
Carboplatin is the second FDA-approved antitumor agent from the Platinum drug family.  
It has a similar antitumor spectrum to cisplatin, and has cross-resistance with cisplatin.  
Carboplatin is generally more tolerable than cisplatin, and its dose limiting toxicity is 
myelosuppression.  Carboplatin’s mechanism of action is similar to cisplatin, however, 
cyclobutane-1,1-dicarboxylate in carboplatin makes it more resistant to aquation and therefore  
slower to form carboplatin-DNA adducts (Knox, Friedlos, Lydall, & Roberts, 1986). 
3.1.3. Doxorubicin   
Doxorubicin is an anthracyline anticancer drug.  It was first extracted from Streptomyces 
peucetius var. caesius (Arcamone et al., 1969).  It is used for the treatment of variety of cancers, 
such as breast cancer, small-cell lung cancer, ovarian cancer, acute lymphoblastic leukemia, 
Hodgkin lymphoma, etc.  There are two main mechanisms of its cytotoxicity, intercalation into 
DNA and generation of free radicals.  The first mechanism inhibits the DNA synthesis while the 
second leads to DNA and cell membrane damage (Thorn et al., 2011). 
3.1.4. Gemcitabine   
Gemcitabine is a nucleoside analog of deoxycytidine that exhibits anticancer activity in 
breast cancer, non-small cell lung cancer and bladder cancer.  Gemcitabine is cell phase specific, 
which kills cells during DNA synthesis (S-phase).  It is metabolized intracellularly into 
diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides, both of which attribute to 
inhibition of DNA synthesis (Eli Lilly, 1996). 
3.2. Materials and Methods 
3.2.1. Materials   
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A549 cell line was purchased from ATCC (VA, US).  A549-iRFP cell line was purchased 
from Imanis Life Sciences (MN, US).   RPMI 1640, DMEM, Collagen, Trypsin-EDTA, and 1% 
penicillin-streptomycin were purchased from Thermo-Fisher.  Puromycin was purchased from 
Alfa Aesar (MA, US).  Fetal bovine serum was purchased from Gemini Bio-Products (CA, US).  
Ultra Cruz® Black/Clear Flat bottom 96-well microplates were purchased from Santa Cruz (CA, 
US).  White Flat Bottom 96-well microplates and 96-well Spheroid microplates were purchased 
from Corning Life Science (NY, US).  CellTiter 96® AQueous One Solution Cell Proliferation 
Assay and CellTiter-Glo® 3D Cell Viability Assay kits were purchased from Promega 
Corporation (Madison, WI, US).  Cisplatin and Doxorubicin Hydrochloride were purchased from 
BIOTANG Inc. (MA, US).  Carboplatin was purchased from ChemScene llc (NJ, US).  
Gemcitabine Hydrochloride was purchased from LC Laboratory (MA, US) 
3.2.2. Cell Culture Maintenance   
A549 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum 
(Gemini, CA, US) and 1% Penicillin-Streptomycin (Corning Life Science, NY, US).  A549-iRFP 
cells were maintained in DMEM supplemented with 10% fetal bovine serum (Gemini, CA, US), 
1% Penicillin-Streptomycin (Corning Life Science, NY, US), and 1 μg/ml puromycin (Alfa 
Aesar, MA, US).  Cells were grown in 5% CO2 at 37 °C and passaged at 85% confluence (3~4 
days). 
3.2.2.1. Cytotoxicity Assay for Selected Anticancer Drugs on 2D Monolayer Cells.  
A549 and A549-iRFP cells were seeded onto Ultra Cruz® Clear and Black flat-bottom 96-well 
microplates (Santa Cruz, CA, US), respectively, at seeding density of 5000 cells/well.  Cells 
were grown overnight to be prepared for the cytotoxicity assay.  The growth media was then 




drug was dissolved in water and diluted with media by 10 fold to prepare the highest 
concentration of the drug solution in media, followed by further dilution with media to 
decremental concentrations.  Drug solutions in media were replaced by growth media after 72 
hours and/or 48 hours incubation.  Reagent solution (20 µl/well) of the CellTiter 96® AQueous 
One Solution Cell Proliferation Assay was then added and incubated for 3 hours, after which UV 
absorbance (λ=490 nm) was read by a Synergy HT microplate reader.  One set of cells were 
treated with drug-free growth media for each experiment and assayed in parallel as control, 
whose viability was taken as 100%.  Wells in microplates with no seeded cells were also assayed 
in parallel as the blank.  Viability for each assay sample at various drug concentrations were 







Samples were evaluated in triplicates or more. 
3.2.2.2. Cytotoxicity Assay for Selected Anticancer Drugs in 3D MCS Cell Model.  
A549 and A549-iRFP cells were seeded 5000 cells/well onto Corning 96-well spheroid 
microplates (Corning Life Science, NY, US) to form MCS as described previously (Chapter 
section 2.2.3).  Spheroids were grown to diameter ~ 500 μm in 5 to 6 days after seeding to be 
prepared for the assay.  Media was then replaced by drug solutions in media at decremental 
concentrations, for which the drug (except cisplatin) was dissolved in water and diluted by 10 
fold with media to prepare the highest concentration, followed by further dilution with media to 
decremental concentrations.  Because of its poor solubility in water, cisplatin was directly 
dissolved in media and then further diluted with media to decremental concentrations.  Drug 
solutions in media were replaced by 100 µl growth media after 48-72 hours incubation with 
cells.  Reagent solution (100 µl) of CellTiter-Glo® 3D Cell Viability Assay was added to each 
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well, and the plates were shaken for 5 min and then incubated for 25 min, after which 
luminescence was recorded by a Synergy HT microplate reader.  One set of cells were treated 
with drug-free growth media for each experiment and assayed in parallel as control, whose 
viability was taken as 100%.  Viability for each sample at various drug concentrations were 




× 100% Equation 3.2 
 
Samples were evaluated in triplicates or more. 
3.2.3. Data Analysis   
Data are presented as mean ± standard deviation (SD) for all cytotoxicity assay studies.  
IC50 values were estimated by nonlinear regression [log(inhibitor) vs.  response, Variable slope, 
four parameters] using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla, CA).  The 
statistical analysis is performed by unpaired t test to compare statistical difference of IC50 
between monolayer and MCS using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla, 
CA).  Results with P < 0.05 were accepted as statistically significant. 
3.3. Results 
3.3.1. Sensitivity of A549 Monolayer Cells and MCS to Anticancer Drugs   
A549 cells, either in monolayer or in MCS, were treated with different anticancer drugs 
at decremental concentrations and their viability is presented as dose-response curves in Figure 
7.  Concentration of different anticancer drugs that is required to inhibit fifty percent growth 
(IC50) of A549 monolayer cells and MCS were then estimated from data in Figure 7 using the 
GraphPad Prism software and are shown in Table 4.  The four selected chemotherapy drugs were 
firstly tested in 2D monolayer cells.  Three of the drugs, namely cisplatin, carboplatin and 
doxorubicin inhibited most viability of the monolayer cells below 200 μM except for 
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gemcitabine.   The four drugs were then evaluated in 3D MCS cell culture.  Except for 
gemcitabine, which was not active at the highest dose tested, the drugs generated typical dose-
response curves in 3D MCS.  IC50 values in MCS was estimated with high reproducibility.  
Therefore, the 3D MCS viability assay can be readily used to reliably evaluate drug activity.  
Moreover, table 4 compares IC50 values between A549 monolayer cells and A549 MCS, which 
reveals higher IC50 values in MCS (e.g., 10-fold higher IC50 of doxorubicin for A549 MCS than 
A549 monolayer cells). 
MCS have properties that are similar to that of solid tumor, which monolayer cells don’t 
have, such as hypoxic and acidic microenvironment, increased cell-cell and cell-matrix 
interactions and cellular heterogeneity.  Those properties may lead to inability of compounds to 
penetrate through cells or to alter cell signaling, which in turn induces drug resistance in 3D 
MCS.  However, the literature has also reported cases of increased drug sensitivity in 3D MCS 
over monolayer cells.  Trastuzumab, a targeted anticancer drug, can reduce 48% of SKBR-3 3D 
MCS growth but only 16% of the corresponding monolayer cells at the same concentration.  The 
authors of this investigation concluded it was because the 3D MCS was more representative of 
the HER2 signaling pathway in tumors in vivo (Pickl & Ries, 2009).  Still, another example is 
that 2D A431.H9 cells maintained 72% viability after treatment with tirapazamine (TPZ), while 
the corresponding 3D MCS maintained only 40% viability.  This higher sensitivity of 3D MCS 
to the drug was explained by the need of TPZ to be activated by hypoxia, which was prominent 
in 3D MCS but not in 2D monolayer cells (Tung et al., 2011).  These two examples highlight the 
fact that MCS do not necessarily induce drug resistance, but the combination of the drug and the 
three dimensional cellular environment in MCS can substantially alter the drug effect and 




Figure 7. Representative dose-dependant viability curves of A549 monolayer cells (blue) and 
MCS (red) after exposure to anticancer drugs. (A) cisplatin, (B) carboplatin, (C) doxorubicin, 
and (D) gemcitabine. Data presented as mean ± SD, N ≥3. 
 
Table 4 
IC50 Values of Different Anticancer Drug on A549 Monolayer Cells and MCS. Data Presented 
as Mean ± SD Of Three Separate Experiments. (P>0.05 for Unpaired T Test).  
 
2D (μM) 3D (μM)  
P value between 
IC50 on 2D and 3D 
cisplatin 9.07 ± 3.27 20.71 ± 2.63 2.28 0.0040 
carboplatin 131.80 ± 10.66 188.90 ± 18.68 1.43 0.0100 
doxorubicin 0.63 ± 0.23 6.57 ± 2.88 10.37 0.0302 
gemcitabine >100 >100 N/A N/A 
 
 
3.3.2. Sensitivity of A549 Monolayer Cells and MCS to Anticancer Drugs   
A549-iRFP cells, either in monolayer or in MCS, were treated with different anticancer 
drugs at decremental concentrations and their viability is presented as dose-response curves in 
Figure 8.  IC50 of different anticancer drugs on A549-iRFP MCS and monolayer cells were 






values are shown in Table 5.  The four anticancer drugs showed similar results in A549-iRFP 
cells compared to A549.  Specifically, gemcitabine is still not active at the highest dose tested 
while dose-response curves are prominent for cisplatin, carboplatin, and doxorubicin in both 2D 
and 3D cultures.  Similar to the data for A549 cells (Table 4), the IC50 value of cisplatin, 
carboplatin, and doxorubicin against A549-iRFP 3D MCS was substantially higher than that 
against A549-iRFP monolayer cells (Table 5).  However, as is shown in Table 6, parts of the 
IC50 values of A549-iRFP for both the 2D monolayer cells and the 3D MCS are comparable to 
those in A549 (P > 0.05 for unpaired t test), but some are statistically different (P < 0.05 for 
unpaired t test).  A549-iRFP is parental A549 cells transduced with LV-iRFP-P2A-Puro 
(LV032), so it does not necessarily exhibit exact same drug response as A549, there are still 
some limitations of using A549-iRFP to represent A549. But in general, A549-iRFP shows same 
trend as A549 that 3D MCS needs higher concentration to inhibit 50% of cell growth than the 




Figure 8. Representative dose-dependant viability curves of A549-iRFP monolayer cells (blue) 
and MCS (red) after exposure to anticancer drugs. (A) cisplatin, (B) carboplatin, (C) 






IC50 Values of Different Anticancer Drugs on A549-iRFP Monolayer Cells and MCS. Data 
Presented as Mean ± SD of Three Separate Experiments. (P>0.05 for Unpaired T Test). 
 
2D (μM) 3D (μM)  P value between IC50 on 2D and 3D 
cisplatin 12.25 ± 1.04 50.67 ± 15.29 4.14 0.0010 
carboplatin 197.24 ± 33.61 265.63 ± 23.31 1.35 0.0221 
doxorubicin 0.9 ± 0.45 4.18 ± 0.76 4.65 0.0008 
gemcitabine >100 >100 N/A N/A 
 
 
Table 6  
Comparison of IC50 Between A549 and A549-iRFP of Different Drugs on Their Corresponding 
Culture Type. (P>0.05 for Unpaired T Test). 
  








on 3D   
cisplatin P>0.05 1.35 0.0233 2.45 
carboplatin 0.0297 1.50 0.0112 1.41 




Drug response curves of cisplatin, carboplatin and doxorubicin were successfully 
generated in MCS of both A549 and A549-iRFP cell lines.  The 3D cytotoxicity protocol 
described in this chapter can be used to evaluate compounds as potential anti- lung cancer drugs 
because it is reproducible and easy to operate.  Higher concentration of the tested anticancer 
drugs are needed to inhibit 50% the cell viability in MCS than monolayer A549 and A549-iRFP 
cells, which can be explained by the MCS properties that are absent in monolayer cells (Chapter 
I), such as hypoxic and acidic microenvironment, cellular heterogeneity and increased cell-cell 
and cell-matrix interactions. 
  
𝐼𝐼𝐼𝐼50(3𝐷𝐷,   𝐴𝐴549−𝑖𝑖𝑅𝑅𝑅𝑅𝑅𝑅)
𝐼𝐼𝐼𝐼50(3𝐷𝐷,   𝐴𝐴549)
 (𝑓𝑓𝑓𝑓𝜇𝜇𝑓𝑓) 
𝐼𝐼𝐼𝐼50（3𝐷𝐷,   𝐴𝐴549−𝑖𝑖𝑅𝑅𝑅𝑅𝑅𝑅)







CHAPTER 4: TREATING MCS OF LUNG CANCER CELLS WITH CHEMOTHERAPY 
AGENTS BASED ON CLINICAL REGIMENS 
 
4.1. Introduction 
4.1.1. Clinical Regimens   
Cisplatin, carboplatin, vinorelbine, docetaxel, etoposide, gemcitabine, pemetrexed and 
paclitaxel are commonly used chemotherapy drugs against NSCLC.  These drugs are usually 
used in combinations in clinical regimens to treat NSCLC.  Table 7 lists preferred chemotherapy 
regimens for NSCLC neoadjuvant and adjuvant therapy based on National Comprehensive 




 NCCN Guidelines® NSCLC Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy  
cisplatin 75 mg/m2  day 1  + pemetrexed 500 mg/m2 day 1 every 21 days for 4 cycles 
cisplatin 75 mg/m2  day 1  + gemcitabine 1250 
mg/m2  
days 1 and 8, every 21 days for 4 cycles 
cisplatin 75 mg/m2  day 1  + docetaxel 75 mg/m2 day 1 every 21 days for 4 cycles 
cisplatin 50 mg/m2 days 1 and 8 + vinorelbine 25 mg/m2 days 1, 8, 15, and 22, every 28 day for 4 
cycles 




day 1  + vinorelbine 25-30 
mg/m2 
days 1 and 8, every 21 days for 4 cycles 
cisplatin 100 mg/m2 day 1  + etoposide 100 mg/m2 days 1-3 every 28 day for 4 cycles 
Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin 
carboplatin AUC 6 day 1  + paclitaxel 200 mg/m2 day 1 every 21 days for 4 cycles 
carboplatin AUC 5 day 1  + gemcitabine 1000 mg/m2 days 1 and 8, every 21 days for 4 cycles 
carboplatin AUC 5 day 1  + pemetrexed 500 mg/m2 day 1 for nonsquamous every 21 days for 4 
cycles 
 
4.1.2. Incubation Time    
In most in vitro cytotoxicity studies, cells are exposed to drug for 48- or 72-hour 
continuous exposure (Larsson et al., 2020; Nordin et al., 2019).  In fact, many small molecule 
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drugs are metabolized or eliminated quickly, so that their half-life in plasma is much shorter than 
48 hours.  Therefore, it is irrational to use 48- or 72-hour continuous treatment for all drugs and 
important to consider the PK of a drug when designing experiments to treat MCS with the drug.  
Take cisplatin as an example, the peak plasma concentration is about 10 µM and its half-life is 
less than 1 hour in patients (Himmelstein et al., 1981).  A rational experimental design with 
cisplatin would be to incubate cells with low concentrations for only a few hours instead of using 
100 µM and with incubations of 24-72 h (C. Wang & Youle, 2012).   
In this study, because it is exceedingly cumbersome for a cell culture system to precisely 
mimic the exponential decrease of the drug concentration as we see in the in vivo PK, an 
approximation of the PK was simulated by lowering the concentration to ¼ of the original after 
two half-lives,  and then from ¼ of the original concentration to 0 after another 2 half-lives.  
4.2. Materials and Methods 
4.2.1. Materials   
A549-iRFP cell line was purchased from Imanis Life Sciences (MN, US).  DMEM, 
Collagen, Trypsin-EDTA, 1% penicillin-streptomycin were purchased from Thermo-Fisher.  
Puromycin was purchased from Alfa Aesar (MA, US).  Fetal bovine serum was purchased from 
Gemini Bio-Products (CA, US).  White Flat Bottom 96-well microplate and 96-well Spheroid 
microplate were purchased from Corning Life Science (NY, US).   CellTiter-Glo® 3D Cell 
Viability Assay kits were purchased from Promega Corporation (Madison, WI, US).  Carboplatin 
was purchased from ChemScene llc (NJ, US).  Gemcitabine Hydrochloride was purchased from 
LC Laboratory (MA, US). 
4.2.2. Cell Culture Maintenance   
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A549-iRFP was maintained in DMEM supplemented with 10% fetal bovine serum 
(Gemini, CA, US), 1% Penicillin-Streptomycin (Corning Life Science, NY, US) and 1 μg/ml 
puromycin (Alfa Aesar, MA, US).  Cells were grown in 5% CO2 at 37 °C and passaged at 85% 
confluence every 3~4 days. 
4.2.3. 3D MCS   
A549-iRFP cells were seeded at 5000 cells/well onto Corning 96-well spheroid 
microplates (Corning Life Science, NY, US) to form MCS as described previously (Chapter II 
2.2.3).  Spheroids were ready for experiment when the diameter reached 500 μm, typically in 
5~6 days.  At the beginning of the drug treatment, the growth media were replaced by drug 
solutions in media.  Besides drug treatment, media was partially exchanged every other day by 
replacing 100 µl/well media in microplates with 100 µl/well fresh media to ensure a total media 
volume of 200 µl. 
4.2.4. Scheduled Treatment of MCS with Anticancer Drugs  
4.2.4.1. Targeted levels of drug exposure based on clinical regimen.  Among all 
the regimens NCCN recommend, carboplatin AUC=5 on day 1, gemcitabine 1000 mg/m2 on 
days 1 and 8, every 21 days for 4 cycles was chosen to be mimicked on MCS because both drugs 
are in the list of the anticancer drugs under this thesis’ studies.   
4.2.4.2. Grouping.  Experimental groups were designed following the criteria 
discussed below.  Control groups were also prepared for each drug/drug combination per 
treatment duration.  The grouping details are listed in Table 7. 
4.2.4.3. Duration of drug exposure.  Based on our previous lab experience, MCS 
has been cultured for 20 days (Yingbo, 2019).  So, in this study, the total selected time frame of 
drug treatment on MCS was 28 days which is 7 days/cycle, 4 cycles in total, instead of 21 days x 
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4 cycles = 84 days for the clinical regimen.  Each cycle for the MCS treatment is 7 days, where 
carboplatin was given on day 1 of each cycle and gemcitabine on day 1 and day 3 of each cycle.  
In order to mimic drug concentration decrease due to metabolism and elimination, some groups 
of MCS were scheduled to have media change according to half-life of the drug.  Specifically, 
the drug concentration was lowered to ¼ of the original after 2 half-lives, and then further 
lowered to 0 after another 2 half-lives.  Half-lives of gemcitabine and carboplatin are considered 
1 hour and 2 hours, respectively,  according to prior PK studies (Eli Lilly, 1996; van der Vijgh, 
1991).  For comparison to the PK-based, cycled drug exposure, additional groups of MCS were 
also continuously exposed to drug(s) for 48 hours.  The schematic diagram of concentration 
changes is shown in Figure 9. 
4.2.4.4. Drug Concentration.  The concentration of the drugs to treat MCS are 
determined based on two criteria.  One criterion is to use clinically relevant concentrations.  
According to NCCN guideline, carboplatin is dosed to target AUC=5, which corresponds to 44.65 
μM initial concentration for groups that are treated in cycles according to the drug  half-life, or 
corresponds to 4.65 μM in case of 48-hour continuous drug exposure.  Gemcitabine’s initial 
concentration is based on its peak plasma concentration (PPC) of about 30 μM when dosed at 1000 
mg/m2 (Ciccolini, Serdjebi, Peters, & Giovannetti, 2016).  The other criterion is to use IC50 values 
of different drugs on the monolayer cells which obtained from the in vitro studies of this thesis.  
Therefore, 150 μM was used on carboplatin. 
To start the treatment of MCS with a drug, the media (200 µl/well) in microplates was 
replaced by 200 µl/well freshly made drug solutions in media.  In order to decrease the 
concentration of a single drug to ¼ of the initial level at the double half-life time, 150 of 200 µl 
drug-containing media in each well was replaced by fresh, drug-free media.  To mimic the PK for 
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a two-drug combination, assuming gemcitabine and carboplatin is evenly distributed in the media, 
so 150 µl of the initial 200 µl drug-containing media was replaced by freshly prepared, more 
diluted carboplatin solution in media at gemcitabine’s first and second half-life so that the 
concentration of each of the two drugs in the combination reaches the target concentration.  At the 
end of drug exposure, all drug-containing media was replaced by fresh, drug-free media (see Table 





Detailed Grouping Information and Scheme of Treatment Action 
  group number drug 








44.65 μM carboplatin for 2 carboplatin 
half-life (4 hours), then 11.16 μM for 
another 2 carboplatin half-life (4 
hours) 




150 μM carboplatin for 2 carboplatin 
half-life (4 hours), then 37.5 μM for 
another 2 carboplatin half-life (4 
hours) 




30 μM gemcitabine for 2 gemcitabine 
half-life (2 hours), then 7.5 μM for 
another 2 gemcitabine half-life (2 
hours) 
6 continuous exposure 30 µM gemcitabine for 48 hours 
7 gemcitabine PPC continuous exposure 
30 µM gemcitabine and 4.65 μM 




30 μM gemcitabine and 44.65 μM 
carboplatin for 2 gemcitabine/ 1 
carboplatin half-life (2 hours), then 7.5 
μM gemcitabine and 22.33 μM 
carboplatin for another 2 gemcitabine 
half-life (2 hours), followed with 11.16 
μM carboplatin for 2 carboplatin half-







1 and 3 (t1/2 
of 
carboplatin) 
change media at 2nd carboplatin half-
life (4 hours), then incubate for 




2 and 4 
(continuous 
exposure) 
incubate for 48 hours 
11 
follow group 
5 (t1/2 of 
gemcitabine) 
change media at 2nd gemcitabine half-
life (2 hours), then incubate for 




6 and 7 
(continuous 
exposure) 




(Table 8 Continued) 
 13   
follow group 




change media at 2nd gemcitabine half-
life (2 hours), incubate for another 2 
gemcitabine half-life (2 hours) 
followed, then change media again 




Figure 9. Schematic diagram of concentration changes. (A). continuous exposure group; (B). 
PK-mimetic carboplatin group; (C) PK-mimetic gemcitabine group; (D) PK-mimetic 
combination group. 
 
4.2.4.5. Viability.  The fluorescent signal (λex =685 nm, λem = 700 nm) of the near-
infrared fluorescent protein iRFP from A549-iRFP was recorded by an Odyssey® Infrared 
Imaging 205 System (LI-COR® Biosciences, Lincoln, NE, USA) at the 700 nm channel to 
measure the iRFP expression as a dynamic indicator of MCS viability.  On the last day of 
viability monitoring, all the MCS were also assessed by the CellTiter-Glo® 3D Cell Viability 
Assay, which measures the cellular ATP level.   
The iRFP level and the cellular ATP level of MCS on the last day of viability monitoring 
were used to calculate the iRFP inhibition rate and the cellular ATP inhibition rate using the 




𝑉𝑉𝑖𝑖𝑖𝑖𝑖𝑖 𝑉𝑉𝑖𝑖ℎ𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑓𝑓𝑖𝑖 𝑟𝑟𝑉𝑉𝑉𝑉𝑟𝑟 =
𝑉𝑉𝑖𝑖𝑖𝑖𝑖𝑖 𝜇𝜇𝑟𝑟𝑙𝑙𝑟𝑟𝜇𝜇 (𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑−𝑡𝑡𝑑𝑑𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠𝑡𝑡𝑡𝑡 𝑑𝑑𝑑𝑑𝑔𝑔𝑑𝑑𝑠𝑠)
𝑉𝑉𝑖𝑖𝑖𝑖𝑖𝑖 𝜇𝜇𝑟𝑟𝑙𝑙𝑟𝑟𝜇𝜇(𝑐𝑐𝑔𝑔𝑡𝑡𝑡𝑡𝑑𝑑𝑔𝑔𝑠𝑠 𝑑𝑑𝑑𝑑𝑔𝑔𝑑𝑑𝑠𝑠)
× 100% Equation 4.1 
𝑐𝑐𝑟𝑟𝜇𝜇𝜇𝜇𝑐𝑐𝜇𝜇𝑉𝑉𝑟𝑟 𝐴𝐴𝐴𝐴𝑖𝑖 𝑉𝑉𝑖𝑖ℎ𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑓𝑓𝑖𝑖 𝑟𝑟𝑉𝑉𝑉𝑉𝑟𝑟 =
𝐴𝐴𝐴𝐴𝑖𝑖 𝜇𝜇𝑟𝑟𝑙𝑙𝑟𝑟𝜇𝜇(𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑−𝑡𝑡𝑑𝑑𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠𝑡𝑡𝑡𝑡 𝑑𝑑𝑑𝑑𝑔𝑔𝑑𝑑𝑠𝑠)
𝐴𝐴𝐴𝐴𝑖𝑖 𝜇𝜇𝑟𝑟𝑙𝑙𝑟𝑟𝜇𝜇(𝑐𝑐𝑔𝑔𝑡𝑡𝑡𝑡𝑑𝑑𝑔𝑔𝑠𝑠 𝑑𝑑𝑑𝑑𝑔𝑔𝑑𝑑𝑠𝑠)
× 100% Equation 4.2 
 
4.2.5. Data Analysis   
Data are presented as mean ± standard deviation (SD).  When there were more than two 
groups, the statistical analysis was performed by Brown-Forsythe and Welch one-way analysis 
of variance (ANOVA) using GraphPad Prism 8.0 Software.  Tamhane’s T2 multiple 
comparisons test analysis was performed to compare between groups, unpaired t-test was 
performed when there were only two groups to compare.  Results with P < 0.05 were accepted as 
statistically significant.   
4.3. Results and Discussion 
4.3.1. A549-iRFP MCS’s Response to Carboplatin   
Figure 10 shows the growth curves of carboplatin treated MCS as shown by the increase 
of the iRFP fluorescence.  Viability of MCS on the last day was extracted from Figure 10 and 
plotted in Figure 11 (A).  The inhibition of viability (Figure 11 B) was calculated from the iRFP 
level of the last day, where the iRFP level of a treatment group was divided by the iRFP level 
from its drug-free control group (Equation 4.1).  3D viability assay was also used to 
independently validate the iRFP-based MCS viability and plotted in Figure 11 (C).  The data in 
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Figure 13 (C) was extracted and used to calculate the inhibition of viability according to the 3D 
viability assay of cellular ATP (Figure 11 D, Equation 4.2).   
 
 





There is no statistic difference (P>0.05 by Brown-Forsythe and Welch ANOVA) between 
two drug-free control groups (both treated with drug-free media, one incubated for 48 hours, one 
changed media according to half-life) in Figure 11 (A, C), indicating changing media at half-live 
doesn’t affect MCS viability.  The 150 µM, 48-hour treatment group statistically inhibited more 
cell growth (P<0.05 by Brown-Forsythe and Welch ANOVA) than 150 µM, PK simulation 
Figure 11. Viability and inhibition rate of carboplatin-treated A549-iRFP MCS. Data presented 
as mean ± SD, N ≥4. (A) Viability by iRFP level; (B) Inhibition rate calculated from iRFP level; 
(C) Viability by cellular ATP level using CellTiter-Glo® 3D Cell Viability Assay; (D) Inhibition 




group in Figure 11 (A-D).  Even though these two groups share the same concentration, they 
have different treatment duration, which resulted in different inhibition effect.  Continuous drug 
exposure for 48-hour or 72-hour is commonly used in many cell culture assays for drug-
screening.  However, most drugs metabolize quickly in body and thus does not maintain the 
initial concentration at the site of action for 48 hours to 72 hours.  Therefore, changing media to 
mimic the decrease of drug concentration in vivo would improve the clinical relevance of drug 
screening in cell culture.  The 4.65 µM, 48-hour treatment group inhibit a little bit more than 
44.65 µM, PK simulation group, but the difference is not statistically significant (P>0.05 by 
Brown-Forsythe and Welch ANOVA, Figure 11 A-D).  Although these two groups were treated 
with different concentrations and duration of drug exposure, they had the same AUC.  Their 
similar viability inhibition rates indicate that neither longer duration of drug exposure nor higher 
drug concentration is superior.  The similar viability inhibition also suggest that AUC is a better 
predictor of the efficacy of carboplatin.  Results in Figure 11 A, B are consistent with Figure 11 
C, D, indicating that, similar to cellular ATP level, the iRFP fluorescent signal is a reliable 
indicator of MCS growth and viability.  It also very convenient and can be assessed repeatedly, 
whereas by measuring ATP level, MCS will have to be sacrificed.  However, large standard 
deviations are seen using iRFP signal shown in Figure 10.   This is probably because the media 
change sometimes moved MCS off the center in a well, which increased the absorption of the 
fluorescent signal by the black wall of the 96-well plate, which in turn artificially lowered the 
reading and increased the g variances.  According to drug responses from MCS, it shows that 
MCS can be used in intensive and long-term cytotoxicity study. 
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4.3.2. A549-iRFP MCS’s Response to Gemcitabine   
Figure 12 shows the growth curves of gemcitabine treated MCS, as indicated by the 
change of viability determined by the fluorescence of cellular iRFP.  Moreover, viability of MCS 
on the last day of the experiment was re-plotted in Figure 13 A.  Figure 13A is then re-plotted in 
Figure 13 B, where the decrease of iRFP fluorescence was divided by the iRFP fluorescence of 
control MCS that were not exposed to the anticancer drug to indicate growth inhibition (Equation 
4.1).  For cross-validation, cellular ATP of MCS at the end of the experiment was also measured 
by the 3D viability assay (Figure 13 C) and re-plotted into growth inhibition in Figure 13 D by 
dividing the decrease of cellular ATP with that of control MCS (Equation 4.2). 
 
 
Figure 12. Growth curves of gemcitabine treated A549iRFP MCS, according to the fluorescence 





Figure 13. Viability and inhibition rate of gemcitabine-treated A549-iRFP MCS. Data presented 
as mean ± SD, N ≥4. (A) Viability indicated as iRFP level; (B) Inhibition rate calculated from 
iRFP level; (C) Viability read by CellTiter-Glo® 3D Cell Viability Assay; (D) Inhibition rate 
calculated from 3D cell viability assay. **P< 0.002, ****P<0.0001 for Brown-Forsythe and 
Welch ANOVA. ++P< 0.002, ++++P<0.0001 for unpaired t test. 
 
There is no statistic difference (P>0.05 by Brown-Forsythe and Welch ANOVA) between 
the two drug-free control groups (both treated with drug-free media, one incubated for 48 hours, 
one changed media according to half-life)  in Figure 13 (A, C), indicating that changing media at 
the half-live time points did not affect the MCS viability.  Gemcitabine that was treated at 30 µM 
for 48- inhibit most cell growth in this study, which is not consistent with IC50 viability curve 
done in Chapter III.  In this case, it is almost complete inhibition whereas in previous scenario, 
none can inhibit more than 50%.  This could probably relate to batch difference of gemcitabine.  
The 30 µM, 48-hour treatment group shows statistically lower viability (P<0.05 by Brown-
Forsythe and Welch ANOVA) than the 30 µM, PK simulation group in Figure 13 (A, C) 
according to iRFP fluorescence, which is consistent with the significantly different cellular ATP 
levels between the two groups (Figure 13 B and D), both strongly indicating that continuous drug 
exposure over 48 hours inhibited MCS viability significantly more (P<0.05 by Brown-Forsythe 
and Welch ANOVA) than pulsed exposure according to the drug’s PK in vivo.  This 
phenomenon is also consistent with what is seen in carboplatin treated MCS groups (Figure 11).  
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Similar to results on carboplatin-treated MCS groups (Figure 10), reproducible and easily 
assessed iRFP signal shows relatively large standard deviations in gemcitabine-treated MCS 
(Figure 12).  Furthermore, MCS show sensitive drug responses, this indicates its ability to be 
used in intensive, long-term cytotoxicity study. 
4.3.3. Response of A549-iRFP MCS to Drug Combinations   
Figure 14 shows the growth curves of MCS that are treated with a combination of 
carboplatin and gemcitabine based on the fluorescence of cellular iRFP.  Viability of such MCS 
on the last day was re-plotted in Figure 15 A, from which growth inhibition was derived (Figure 
15 B) by dividing the decrease of iRFP fluorescence with iRFP fluorescence of control MCS that 
was not exposed to any drug (Equation 4.1).  The 3D viability assay based on cellular ATP 
measurements was also used to cross-validate the MCS viability (Figure 15 C), from which 
growth inhibition was derived (Figure 15 D) by  dividing the decrease of cellular ATP with that 
of control MCS that was not exposed to any drug (Equation 4.2).   
 
 
Figure 14. Growth curves of MCS treated with a combination of carboplatin and gemcitabine 




Figure 15. Viability and inhibition rate of carboplatin and gemcitabine-treated A549-iRFP MCS. 
Data presented as mean ± SD, N ≥4. (A) Viability indicated as iRFP level; (B) Inhibition rate 
calculated from iRFP level; (C) Viability read by CellTiter-Glo® 3D Cell Viability Assay; (D) 
Inhibition rate calculated from 3D cell viability assay. **P< 0.002, ****P<0.0001 for Brown-
Forsythe and Welch ANOVA. ++P< 0.002, ++++P<0.0001 for unpaired t test. 
 
There is statistically significant difference (P<0.05 by Brown-Forsythe and Welch 
ANOVA) between drug-free control groups of 48-hour and the one that changes media 
according to gemcitabine and carboplatin’s half-life.  The lower viability in the PK simulation 
group in Figure 15 (A, C) is probably related to the fact that PK simulation group had media 
changes three times as often as the continuous exposure control group.  This result indicates that 
the more time the media is changed the more MCS viability is affected negatively.  Statistic 
difference (P<0.05 by Brown-Forsythe and Welch ANOVA) is also seen between MCS under 
continuous exposure to 30 µM gemcitabine plus 4.65 µM carboplatin group and MCS under 
63 
 
half-life-based exposure to 30 µM gemcitabine plus 44.65 µM carboplatin group, as shown in 
Figure 15 (A, C).  The continuous-exposure group has lower viability comparing to PK mimetic 
group, which is consistent with the finding in single carboplatin and single gemcitabine group 
(Figure 11 B, D and Figure 13 B, D).  By changing media at half-lives, although this is not a 
perfect mimetic of PK changes, it still reduces positive bias from 48-hour or 72-hour continuous 
exposure and gives us a brief insight of how drugs will work in vivo.  Results in Figure 15 A and 
B are consistent with Figure 15 C and D, indicating that the iRFP fluorescent is a reliable signal 
to monitor MCS growth.  Large standard deviations can also be seen in Figure 16.  Similar to 
results on carboplatin-treated MCS and gemcitabine-treated MCS, MCS co-treated with 
carboplatin and gemcitabine shows good viability response at the end of this study, and is able to 
under through intense dosing schedule, indicating its promising future in long-term cytotoxicity 
study. 
4.4. Summary 
MCS of the fluorescent lung cancer cell line A549 iRFP have been treated with 
chemotherapy agents not only by continuous exposure, but also by schedules that mimic the drug 
pharmacokinetics and the clinical chemotherapy regimen.  A number of conclusions can be 
drawn from this study.  Firstly, MCS can be cultured for more than 30 days while under 
complicated drug treatment.  Secondly, all continuous drug exposure inhibited more cell growth 
than the corresponding PK-simulating drug exposure.  Thirdly, changing media at half-lives can 
simulate the drug PK roughly.  Even though it is not a perfect simulation, it better reflects the 
drug efficacy, especially when comparing drugs of different half-lives.  If only continuous drug 
exposure is used to assess anticancer activity, it would bring bias for the potency of certain drugs 
over others.  Fourthly, all cell viability/growth inhibition results based on the near-infrared signal 
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of the fluorescent cellular protein iRFP is consistent with the luminescent signal of cellular ATP 
in the 3D viability assay.  The fluorescent signal of iRFP can be measured multiple times over 
the long course of the experiment without sacrificing the MCS and thus can provide the dynamic 
data of MCS growth.   However, the fluorescent signals carry large standard deviations.  To 
improve the data precision in future study, extra attention is needed to make sure that MCS is 
still placed in the center of the well after each media change.   
Overall, dynamic treatment of MCS with anticancer drugs based on drug PK and clinical 
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